nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolasetron—CYP3A4—prostate cancer	0.208	1	CbGaD
Dolasetron—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0532	0.105	CbGbCtD
Dolasetron—CYP2C9—Nilutamide—prostate cancer	0.0481	0.0947	CbGbCtD
Dolasetron—CYP2C9—Bicalutamide—prostate cancer	0.0481	0.0947	CbGbCtD
Dolasetron—CYP2D6—Bicalutamide—prostate cancer	0.044	0.0866	CbGbCtD
Dolasetron—CYP2D6—Abiraterone—prostate cancer	0.0364	0.0717	CbGbCtD
Dolasetron—CYP2C9—Estrone—prostate cancer	0.0288	0.0567	CbGbCtD
Dolasetron—CYP3A4—Bicalutamide—prostate cancer	0.028	0.0551	CbGbCtD
Dolasetron—CYP3A4—Estramustine—prostate cancer	0.026	0.0512	CbGbCtD
Dolasetron—CYP3A4—Abiraterone—prostate cancer	0.0232	0.0456	CbGbCtD
Dolasetron—CYP3A4—Flutamide—prostate cancer	0.0232	0.0456	CbGbCtD
Dolasetron—CYP2C9—Capecitabine—prostate cancer	0.0218	0.043	CbGbCtD
Dolasetron—CYP3A4—Cabazitaxel—prostate cancer	0.0171	0.0337	CbGbCtD
Dolasetron—CYP3A4—Estrone—prostate cancer	0.0168	0.033	CbGbCtD
Dolasetron—CYP2C9—Estradiol—prostate cancer	0.0165	0.0326	CbGbCtD
Dolasetron—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0149	0.0294	CbGbCtD
Dolasetron—CYP3A4—Conjugated Estrogens—prostate cancer	0.011	0.0216	CbGbCtD
Dolasetron—CYP3A4—Mitoxantrone—prostate cancer	0.00996	0.0196	CbGbCtD
Dolasetron—CYP3A4—Estradiol—prostate cancer	0.00962	0.0189	CbGbCtD
Dolasetron—CYP3A4—Prednisone—prostate cancer	0.00827	0.0163	CbGbCtD
Dolasetron—CYP2D6—Doxorubicin—prostate cancer	0.00674	0.0133	CbGbCtD
Dolasetron—CYP3A4—Etoposide—prostate cancer	0.00628	0.0124	CbGbCtD
Dolasetron—CYP3A4—Docetaxel—prostate cancer	0.00575	0.0113	CbGbCtD
Dolasetron—CYP3A4—Doxorubicin—prostate cancer	0.00428	0.00844	CbGbCtD
Dolasetron—Constipation—Etoposide—prostate cancer	7.32e-05	0.000353	CcSEcCtD
Dolasetron—Dizziness—Estradiol—prostate cancer	7.3e-05	0.000352	CcSEcCtD
Dolasetron—Dysuria—Doxorubicin—prostate cancer	7.3e-05	0.000352	CcSEcCtD
Dolasetron—Hypertension—Capecitabine—prostate cancer	7.28e-05	0.000351	CcSEcCtD
Dolasetron—Dry mouth—Docetaxel—prostate cancer	7.25e-05	0.00035	CcSEcCtD
Dolasetron—Chest pain—Capecitabine—prostate cancer	7.18e-05	0.000347	CcSEcCtD
Dolasetron—Myalgia—Capecitabine—prostate cancer	7.18e-05	0.000347	CcSEcCtD
Dolasetron—Arthralgia—Capecitabine—prostate cancer	7.18e-05	0.000347	CcSEcCtD
Dolasetron—Haematuria—Epirubicin—prostate cancer	7.17e-05	0.000346	CcSEcCtD
Dolasetron—Confusional state—Docetaxel—prostate cancer	7.17e-05	0.000346	CcSEcCtD
Dolasetron—Anxiety—Capecitabine—prostate cancer	7.16e-05	0.000345	CcSEcCtD
Dolasetron—Oedema—Docetaxel—prostate cancer	7.11e-05	0.000343	CcSEcCtD
Dolasetron—Anaphylactic shock—Docetaxel—prostate cancer	7.11e-05	0.000343	CcSEcCtD
Dolasetron—Discomfort—Capecitabine—prostate cancer	7.1e-05	0.000342	CcSEcCtD
Dolasetron—Epistaxis—Epirubicin—prostate cancer	7.09e-05	0.000342	CcSEcCtD
Dolasetron—Feeling abnormal—Etoposide—prostate cancer	7.05e-05	0.00034	CcSEcCtD
Dolasetron—Diarrhoea—Mitoxantrone—prostate cancer	7.04e-05	0.00034	CcSEcCtD
Dolasetron—Dry mouth—Capecitabine—prostate cancer	7.02e-05	0.000339	CcSEcCtD
Dolasetron—Pneumonia—Doxorubicin—prostate cancer	7e-05	0.000338	CcSEcCtD
Dolasetron—Gastrointestinal pain—Etoposide—prostate cancer	7e-05	0.000338	CcSEcCtD
Dolasetron—Shock—Docetaxel—prostate cancer	7e-05	0.000338	CcSEcCtD
Dolasetron—Ill-defined disorder—Prednisone—prostate cancer	6.97e-05	0.000336	CcSEcCtD
Dolasetron—Thrombocytopenia—Docetaxel—prostate cancer	6.96e-05	0.000336	CcSEcCtD
Dolasetron—Rash—Estradiol—prostate cancer	6.96e-05	0.000336	CcSEcCtD
Dolasetron—Drowsiness—Doxorubicin—prostate cancer	6.96e-05	0.000336	CcSEcCtD
Dolasetron—Dermatitis—Estradiol—prostate cancer	6.95e-05	0.000336	CcSEcCtD
Dolasetron—Anaemia—Prednisone—prostate cancer	6.94e-05	0.000335	CcSEcCtD
Dolasetron—Confusional state—Capecitabine—prostate cancer	6.94e-05	0.000335	CcSEcCtD
Dolasetron—Tachycardia—Docetaxel—prostate cancer	6.94e-05	0.000335	CcSEcCtD
Dolasetron—Headache—Estradiol—prostate cancer	6.92e-05	0.000334	CcSEcCtD
Dolasetron—Agitation—Prednisone—prostate cancer	6.9e-05	0.000333	CcSEcCtD
Dolasetron—Oedema—Capecitabine—prostate cancer	6.88e-05	0.000332	CcSEcCtD
Dolasetron—Bradycardia—Epirubicin—prostate cancer	6.87e-05	0.000332	CcSEcCtD
Dolasetron—Angioedema—Prednisone—prostate cancer	6.87e-05	0.000331	CcSEcCtD
Dolasetron—Urticaria—Etoposide—prostate cancer	6.8e-05	0.000328	CcSEcCtD
Dolasetron—Jaundice—Doxorubicin—prostate cancer	6.78e-05	0.000327	CcSEcCtD
Dolasetron—Stomatitis—Doxorubicin—prostate cancer	6.78e-05	0.000327	CcSEcCtD
Dolasetron—Anorexia—Docetaxel—prostate cancer	6.78e-05	0.000327	CcSEcCtD
Dolasetron—Malaise—Prednisone—prostate cancer	6.78e-05	0.000327	CcSEcCtD
Dolasetron—Shock—Capecitabine—prostate cancer	6.77e-05	0.000327	CcSEcCtD
Dolasetron—Abdominal pain—Etoposide—prostate cancer	6.76e-05	0.000326	CcSEcCtD
Dolasetron—Body temperature increased—Etoposide—prostate cancer	6.76e-05	0.000326	CcSEcCtD
Dolasetron—Vertigo—Prednisone—prostate cancer	6.75e-05	0.000326	CcSEcCtD
Dolasetron—Thrombocytopenia—Capecitabine—prostate cancer	6.74e-05	0.000325	CcSEcCtD
Dolasetron—Syncope—Prednisone—prostate cancer	6.74e-05	0.000325	CcSEcCtD
Dolasetron—Tachycardia—Capecitabine—prostate cancer	6.72e-05	0.000324	CcSEcCtD
Dolasetron—Hyperhidrosis—Capecitabine—prostate cancer	6.66e-05	0.000321	CcSEcCtD
Dolasetron—Oedema peripheral—Epirubicin—prostate cancer	6.65e-05	0.000321	CcSEcCtD
Dolasetron—Hypotension—Docetaxel—prostate cancer	6.64e-05	0.000321	CcSEcCtD
Dolasetron—Haematuria—Doxorubicin—prostate cancer	6.63e-05	0.00032	CcSEcCtD
Dolasetron—Loss of consciousness—Prednisone—prostate cancer	6.6e-05	0.000319	CcSEcCtD
Dolasetron—Epistaxis—Doxorubicin—prostate cancer	6.56e-05	0.000317	CcSEcCtD
Dolasetron—Anorexia—Capecitabine—prostate cancer	6.56e-05	0.000317	CcSEcCtD
Dolasetron—Convulsion—Prednisone—prostate cancer	6.51e-05	0.000314	CcSEcCtD
Dolasetron—Visual impairment—Epirubicin—prostate cancer	6.51e-05	0.000314	CcSEcCtD
Dolasetron—Hypertension—Prednisone—prostate cancer	6.49e-05	0.000313	CcSEcCtD
Dolasetron—Rash—Mitoxantrone—prostate cancer	6.49e-05	0.000313	CcSEcCtD
Dolasetron—Dermatitis—Mitoxantrone—prostate cancer	6.48e-05	0.000313	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Docetaxel—prostate cancer	6.48e-05	0.000313	CcSEcCtD
Dolasetron—Headache—Mitoxantrone—prostate cancer	6.44e-05	0.000311	CcSEcCtD
Dolasetron—Hypotension—Capecitabine—prostate cancer	6.43e-05	0.00031	CcSEcCtD
Dolasetron—Myalgia—Prednisone—prostate cancer	6.4e-05	0.000309	CcSEcCtD
Dolasetron—Arthralgia—Prednisone—prostate cancer	6.4e-05	0.000309	CcSEcCtD
Dolasetron—Paraesthesia—Docetaxel—prostate cancer	6.38e-05	0.000308	CcSEcCtD
Dolasetron—Anxiety—Prednisone—prostate cancer	6.37e-05	0.000308	CcSEcCtD
Dolasetron—Bradycardia—Doxorubicin—prostate cancer	6.36e-05	0.000307	CcSEcCtD
Dolasetron—Dyspnoea—Docetaxel—prostate cancer	6.34e-05	0.000306	CcSEcCtD
Dolasetron—Somnolence—Docetaxel—prostate cancer	6.32e-05	0.000305	CcSEcCtD
Dolasetron—Discomfort—Prednisone—prostate cancer	6.32e-05	0.000305	CcSEcCtD
Dolasetron—Hypersensitivity—Etoposide—prostate cancer	6.3e-05	0.000304	CcSEcCtD
Dolasetron—Tinnitus—Epirubicin—prostate cancer	6.29e-05	0.000304	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Capecitabine—prostate cancer	6.27e-05	0.000303	CcSEcCtD
Dolasetron—Flushing—Epirubicin—prostate cancer	6.27e-05	0.000302	CcSEcCtD
Dolasetron—Dyspepsia—Docetaxel—prostate cancer	6.26e-05	0.000302	CcSEcCtD
Dolasetron—Paraesthesia—Capecitabine—prostate cancer	6.18e-05	0.000298	CcSEcCtD
Dolasetron—Decreased appetite—Docetaxel—prostate cancer	6.18e-05	0.000298	CcSEcCtD
Dolasetron—Oedema peripheral—Doxorubicin—prostate cancer	6.15e-05	0.000297	CcSEcCtD
Dolasetron—Asthenia—Etoposide—prostate cancer	6.14e-05	0.000296	CcSEcCtD
Dolasetron—Dyspnoea—Capecitabine—prostate cancer	6.14e-05	0.000296	CcSEcCtD
Dolasetron—Anaphylactic shock—Prednisone—prostate cancer	6.13e-05	0.000296	CcSEcCtD
Dolasetron—Oedema—Prednisone—prostate cancer	6.13e-05	0.000296	CcSEcCtD
Dolasetron—Fatigue—Docetaxel—prostate cancer	6.13e-05	0.000296	CcSEcCtD
Dolasetron—Constipation—Docetaxel—prostate cancer	6.08e-05	0.000293	CcSEcCtD
Dolasetron—Pain—Docetaxel—prostate cancer	6.08e-05	0.000293	CcSEcCtD
Dolasetron—Dyspepsia—Capecitabine—prostate cancer	6.06e-05	0.000292	CcSEcCtD
Dolasetron—Chills—Epirubicin—prostate cancer	6.06e-05	0.000292	CcSEcCtD
Dolasetron—Pruritus—Etoposide—prostate cancer	6.05e-05	0.000292	CcSEcCtD
Dolasetron—Shock—Prednisone—prostate cancer	6.03e-05	0.000291	CcSEcCtD
Dolasetron—Arrhythmia—Epirubicin—prostate cancer	6.03e-05	0.000291	CcSEcCtD
Dolasetron—Visual impairment—Doxorubicin—prostate cancer	6.02e-05	0.00029	CcSEcCtD
Dolasetron—Tachycardia—Prednisone—prostate cancer	5.98e-05	0.000289	CcSEcCtD
Dolasetron—Decreased appetite—Capecitabine—prostate cancer	5.98e-05	0.000289	CcSEcCtD
Dolasetron—Fatigue—Capecitabine—prostate cancer	5.94e-05	0.000286	CcSEcCtD
Dolasetron—Hyperhidrosis—Prednisone—prostate cancer	5.93e-05	0.000286	CcSEcCtD
Dolasetron—Pain—Capecitabine—prostate cancer	5.89e-05	0.000284	CcSEcCtD
Dolasetron—Constipation—Capecitabine—prostate cancer	5.89e-05	0.000284	CcSEcCtD
Dolasetron—Feeling abnormal—Docetaxel—prostate cancer	5.86e-05	0.000283	CcSEcCtD
Dolasetron—Diarrhoea—Etoposide—prostate cancer	5.85e-05	0.000283	CcSEcCtD
Dolasetron—Anorexia—Prednisone—prostate cancer	5.85e-05	0.000282	CcSEcCtD
Dolasetron—Tinnitus—Doxorubicin—prostate cancer	5.82e-05	0.000281	CcSEcCtD
Dolasetron—Gastrointestinal pain—Docetaxel—prostate cancer	5.81e-05	0.000281	CcSEcCtD
Dolasetron—Flushing—Doxorubicin—prostate cancer	5.8e-05	0.00028	CcSEcCtD
Dolasetron—Flatulence—Epirubicin—prostate cancer	5.79e-05	0.000279	CcSEcCtD
Dolasetron—Dysgeusia—Epirubicin—prostate cancer	5.75e-05	0.000278	CcSEcCtD
Dolasetron—Feeling abnormal—Capecitabine—prostate cancer	5.67e-05	0.000274	CcSEcCtD
Dolasetron—Dizziness—Etoposide—prostate cancer	5.66e-05	0.000273	CcSEcCtD
Dolasetron—Gastrointestinal pain—Capecitabine—prostate cancer	5.63e-05	0.000272	CcSEcCtD
Dolasetron—Abdominal pain—Docetaxel—prostate cancer	5.62e-05	0.000271	CcSEcCtD
Dolasetron—Body temperature increased—Docetaxel—prostate cancer	5.62e-05	0.000271	CcSEcCtD
Dolasetron—Chills—Doxorubicin—prostate cancer	5.6e-05	0.00027	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Prednisone—prostate cancer	5.59e-05	0.00027	CcSEcCtD
Dolasetron—Arrhythmia—Doxorubicin—prostate cancer	5.58e-05	0.000269	CcSEcCtD
Dolasetron—Paraesthesia—Prednisone—prostate cancer	5.51e-05	0.000266	CcSEcCtD
Dolasetron—Urticaria—Capecitabine—prostate cancer	5.47e-05	0.000264	CcSEcCtD
Dolasetron—Ill-defined disorder—Epirubicin—prostate cancer	5.45e-05	0.000263	CcSEcCtD
Dolasetron—Abdominal pain—Capecitabine—prostate cancer	5.44e-05	0.000263	CcSEcCtD
Dolasetron—Body temperature increased—Capecitabine—prostate cancer	5.44e-05	0.000263	CcSEcCtD
Dolasetron—Anaemia—Epirubicin—prostate cancer	5.43e-05	0.000262	CcSEcCtD
Dolasetron—Agitation—Epirubicin—prostate cancer	5.4e-05	0.000261	CcSEcCtD
Dolasetron—Dyspepsia—Prednisone—prostate cancer	5.4e-05	0.000261	CcSEcCtD
Dolasetron—Rash—Etoposide—prostate cancer	5.39e-05	0.00026	CcSEcCtD
Dolasetron—Dermatitis—Etoposide—prostate cancer	5.39e-05	0.00026	CcSEcCtD
Dolasetron—Headache—Etoposide—prostate cancer	5.36e-05	0.000259	CcSEcCtD
Dolasetron—Flatulence—Doxorubicin—prostate cancer	5.36e-05	0.000259	CcSEcCtD
Dolasetron—Decreased appetite—Prednisone—prostate cancer	5.33e-05	0.000257	CcSEcCtD
Dolasetron—Dysgeusia—Doxorubicin—prostate cancer	5.32e-05	0.000257	CcSEcCtD
Dolasetron—Malaise—Epirubicin—prostate cancer	5.3e-05	0.000256	CcSEcCtD
Dolasetron—Fatigue—Prednisone—prostate cancer	5.29e-05	0.000255	CcSEcCtD
Dolasetron—Vertigo—Epirubicin—prostate cancer	5.28e-05	0.000255	CcSEcCtD
Dolasetron—Syncope—Epirubicin—prostate cancer	5.27e-05	0.000254	CcSEcCtD
Dolasetron—Constipation—Prednisone—prostate cancer	5.24e-05	0.000253	CcSEcCtD
Dolasetron—Hypersensitivity—Docetaxel—prostate cancer	5.24e-05	0.000253	CcSEcCtD
Dolasetron—Palpitations—Epirubicin—prostate cancer	5.19e-05	0.000251	CcSEcCtD
Dolasetron—Loss of consciousness—Epirubicin—prostate cancer	5.17e-05	0.000249	CcSEcCtD
Dolasetron—Cough—Epirubicin—prostate cancer	5.13e-05	0.000247	CcSEcCtD
Dolasetron—Asthenia—Docetaxel—prostate cancer	5.1e-05	0.000246	CcSEcCtD
Dolasetron—Convulsion—Epirubicin—prostate cancer	5.09e-05	0.000246	CcSEcCtD
Dolasetron—Hypertension—Epirubicin—prostate cancer	5.07e-05	0.000245	CcSEcCtD
Dolasetron—Hypersensitivity—Capecitabine—prostate cancer	5.07e-05	0.000245	CcSEcCtD
Dolasetron—Feeling abnormal—Prednisone—prostate cancer	5.05e-05	0.000244	CcSEcCtD
Dolasetron—Ill-defined disorder—Doxorubicin—prostate cancer	5.05e-05	0.000243	CcSEcCtD
Dolasetron—Pruritus—Docetaxel—prostate cancer	5.03e-05	0.000243	CcSEcCtD
Dolasetron—Anaemia—Doxorubicin—prostate cancer	5.03e-05	0.000243	CcSEcCtD
Dolasetron—Gastrointestinal pain—Prednisone—prostate cancer	5.01e-05	0.000242	CcSEcCtD
Dolasetron—Myalgia—Epirubicin—prostate cancer	5e-05	0.000241	CcSEcCtD
Dolasetron—Chest pain—Epirubicin—prostate cancer	5e-05	0.000241	CcSEcCtD
Dolasetron—Arthralgia—Epirubicin—prostate cancer	5e-05	0.000241	CcSEcCtD
Dolasetron—Agitation—Doxorubicin—prostate cancer	5e-05	0.000241	CcSEcCtD
Dolasetron—Anxiety—Epirubicin—prostate cancer	4.99e-05	0.000241	CcSEcCtD
Dolasetron—Discomfort—Epirubicin—prostate cancer	4.94e-05	0.000239	CcSEcCtD
Dolasetron—Asthenia—Capecitabine—prostate cancer	4.94e-05	0.000238	CcSEcCtD
Dolasetron—Malaise—Doxorubicin—prostate cancer	4.9e-05	0.000237	CcSEcCtD
Dolasetron—Dry mouth—Epirubicin—prostate cancer	4.89e-05	0.000236	CcSEcCtD
Dolasetron—Vertigo—Doxorubicin—prostate cancer	4.89e-05	0.000236	CcSEcCtD
Dolasetron—Syncope—Doxorubicin—prostate cancer	4.88e-05	0.000235	CcSEcCtD
Dolasetron—Urticaria—Prednisone—prostate cancer	4.87e-05	0.000235	CcSEcCtD
Dolasetron—Pruritus—Capecitabine—prostate cancer	4.87e-05	0.000235	CcSEcCtD
Dolasetron—Diarrhoea—Docetaxel—prostate cancer	4.87e-05	0.000235	CcSEcCtD
Dolasetron—Abdominal pain—Prednisone—prostate cancer	4.85e-05	0.000234	CcSEcCtD
Dolasetron—Body temperature increased—Prednisone—prostate cancer	4.85e-05	0.000234	CcSEcCtD
Dolasetron—Confusional state—Epirubicin—prostate cancer	4.84e-05	0.000233	CcSEcCtD
Dolasetron—Palpitations—Doxorubicin—prostate cancer	4.81e-05	0.000232	CcSEcCtD
Dolasetron—Oedema—Epirubicin—prostate cancer	4.8e-05	0.000231	CcSEcCtD
Dolasetron—Anaphylactic shock—Epirubicin—prostate cancer	4.8e-05	0.000231	CcSEcCtD
Dolasetron—Loss of consciousness—Doxorubicin—prostate cancer	4.78e-05	0.000231	CcSEcCtD
Dolasetron—Cough—Doxorubicin—prostate cancer	4.74e-05	0.000229	CcSEcCtD
Dolasetron—Shock—Epirubicin—prostate cancer	4.72e-05	0.000228	CcSEcCtD
Dolasetron—Convulsion—Doxorubicin—prostate cancer	4.71e-05	0.000227	CcSEcCtD
Dolasetron—Diarrhoea—Capecitabine—prostate cancer	4.71e-05	0.000227	CcSEcCtD
Dolasetron—Dizziness—Docetaxel—prostate cancer	4.7e-05	0.000227	CcSEcCtD
Dolasetron—Thrombocytopenia—Epirubicin—prostate cancer	4.7e-05	0.000227	CcSEcCtD
Dolasetron—Hypertension—Doxorubicin—prostate cancer	4.69e-05	0.000227	CcSEcCtD
Dolasetron—Tachycardia—Epirubicin—prostate cancer	4.68e-05	0.000226	CcSEcCtD
Dolasetron—Hyperhidrosis—Epirubicin—prostate cancer	4.64e-05	0.000224	CcSEcCtD
Dolasetron—Myalgia—Doxorubicin—prostate cancer	4.63e-05	0.000223	CcSEcCtD
Dolasetron—Arthralgia—Doxorubicin—prostate cancer	4.63e-05	0.000223	CcSEcCtD
Dolasetron—Chest pain—Doxorubicin—prostate cancer	4.63e-05	0.000223	CcSEcCtD
Dolasetron—Anxiety—Doxorubicin—prostate cancer	4.61e-05	0.000223	CcSEcCtD
Dolasetron—Discomfort—Doxorubicin—prostate cancer	4.57e-05	0.000221	CcSEcCtD
Dolasetron—Anorexia—Epirubicin—prostate cancer	4.57e-05	0.000221	CcSEcCtD
Dolasetron—Dizziness—Capecitabine—prostate cancer	4.55e-05	0.00022	CcSEcCtD
Dolasetron—Dry mouth—Doxorubicin—prostate cancer	4.53e-05	0.000218	CcSEcCtD
Dolasetron—Hypersensitivity—Prednisone—prostate cancer	4.52e-05	0.000218	CcSEcCtD
Dolasetron—Rash—Docetaxel—prostate cancer	4.48e-05	0.000216	CcSEcCtD
Dolasetron—Hypotension—Epirubicin—prostate cancer	4.48e-05	0.000216	CcSEcCtD
Dolasetron—Dermatitis—Docetaxel—prostate cancer	4.48e-05	0.000216	CcSEcCtD
Dolasetron—Confusional state—Doxorubicin—prostate cancer	4.47e-05	0.000216	CcSEcCtD
Dolasetron—Headache—Docetaxel—prostate cancer	4.45e-05	0.000215	CcSEcCtD
Dolasetron—Oedema—Doxorubicin—prostate cancer	4.44e-05	0.000214	CcSEcCtD
Dolasetron—Anaphylactic shock—Doxorubicin—prostate cancer	4.44e-05	0.000214	CcSEcCtD
Dolasetron—Asthenia—Prednisone—prostate cancer	4.4e-05	0.000212	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.37e-05	0.000211	CcSEcCtD
Dolasetron—Shock—Doxorubicin—prostate cancer	4.37e-05	0.000211	CcSEcCtD
Dolasetron—Thrombocytopenia—Doxorubicin—prostate cancer	4.34e-05	0.00021	CcSEcCtD
Dolasetron—Rash—Capecitabine—prostate cancer	4.34e-05	0.000209	CcSEcCtD
Dolasetron—Pruritus—Prednisone—prostate cancer	4.34e-05	0.000209	CcSEcCtD
Dolasetron—Dermatitis—Capecitabine—prostate cancer	4.34e-05	0.000209	CcSEcCtD
Dolasetron—Tachycardia—Doxorubicin—prostate cancer	4.33e-05	0.000209	CcSEcCtD
Dolasetron—Headache—Capecitabine—prostate cancer	4.31e-05	0.000208	CcSEcCtD
Dolasetron—Paraesthesia—Epirubicin—prostate cancer	4.31e-05	0.000208	CcSEcCtD
Dolasetron—Hyperhidrosis—Doxorubicin—prostate cancer	4.29e-05	0.000207	CcSEcCtD
Dolasetron—Dyspnoea—Epirubicin—prostate cancer	4.28e-05	0.000206	CcSEcCtD
Dolasetron—Somnolence—Epirubicin—prostate cancer	4.26e-05	0.000206	CcSEcCtD
Dolasetron—Anorexia—Doxorubicin—prostate cancer	4.23e-05	0.000204	CcSEcCtD
Dolasetron—Dyspepsia—Epirubicin—prostate cancer	4.22e-05	0.000204	CcSEcCtD
Dolasetron—Diarrhoea—Prednisone—prostate cancer	4.2e-05	0.000202	CcSEcCtD
Dolasetron—Decreased appetite—Epirubicin—prostate cancer	4.17e-05	0.000201	CcSEcCtD
Dolasetron—Hypotension—Doxorubicin—prostate cancer	4.15e-05	0.0002	CcSEcCtD
Dolasetron—Fatigue—Epirubicin—prostate cancer	4.13e-05	0.0002	CcSEcCtD
Dolasetron—Pain—Epirubicin—prostate cancer	4.1e-05	0.000198	CcSEcCtD
Dolasetron—Constipation—Epirubicin—prostate cancer	4.1e-05	0.000198	CcSEcCtD
Dolasetron—Dizziness—Prednisone—prostate cancer	4.06e-05	0.000196	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.04e-05	0.000195	CcSEcCtD
Dolasetron—Paraesthesia—Doxorubicin—prostate cancer	3.98e-05	0.000192	CcSEcCtD
Dolasetron—Dyspnoea—Doxorubicin—prostate cancer	3.96e-05	0.000191	CcSEcCtD
Dolasetron—Feeling abnormal—Epirubicin—prostate cancer	3.95e-05	0.000191	CcSEcCtD
Dolasetron—Somnolence—Doxorubicin—prostate cancer	3.95e-05	0.00019	CcSEcCtD
Dolasetron—Gastrointestinal pain—Epirubicin—prostate cancer	3.92e-05	0.000189	CcSEcCtD
Dolasetron—Dyspepsia—Doxorubicin—prostate cancer	3.91e-05	0.000189	CcSEcCtD
Dolasetron—Rash—Prednisone—prostate cancer	3.87e-05	0.000187	CcSEcCtD
Dolasetron—Dermatitis—Prednisone—prostate cancer	3.86e-05	0.000186	CcSEcCtD
Dolasetron—Decreased appetite—Doxorubicin—prostate cancer	3.86e-05	0.000186	CcSEcCtD
Dolasetron—Headache—Prednisone—prostate cancer	3.84e-05	0.000185	CcSEcCtD
Dolasetron—Fatigue—Doxorubicin—prostate cancer	3.83e-05	0.000185	CcSEcCtD
Dolasetron—Urticaria—Epirubicin—prostate cancer	3.81e-05	0.000184	CcSEcCtD
Dolasetron—Constipation—Doxorubicin—prostate cancer	3.79e-05	0.000183	CcSEcCtD
Dolasetron—Pain—Doxorubicin—prostate cancer	3.79e-05	0.000183	CcSEcCtD
Dolasetron—Abdominal pain—Epirubicin—prostate cancer	3.79e-05	0.000183	CcSEcCtD
Dolasetron—Body temperature increased—Epirubicin—prostate cancer	3.79e-05	0.000183	CcSEcCtD
Dolasetron—Feeling abnormal—Doxorubicin—prostate cancer	3.66e-05	0.000176	CcSEcCtD
Dolasetron—Gastrointestinal pain—Doxorubicin—prostate cancer	3.63e-05	0.000175	CcSEcCtD
Dolasetron—Hypersensitivity—Epirubicin—prostate cancer	3.53e-05	0.000171	CcSEcCtD
Dolasetron—Urticaria—Doxorubicin—prostate cancer	3.53e-05	0.00017	CcSEcCtD
Dolasetron—Body temperature increased—Doxorubicin—prostate cancer	3.51e-05	0.000169	CcSEcCtD
Dolasetron—Abdominal pain—Doxorubicin—prostate cancer	3.51e-05	0.000169	CcSEcCtD
Dolasetron—Asthenia—Epirubicin—prostate cancer	3.44e-05	0.000166	CcSEcCtD
Dolasetron—Pruritus—Epirubicin—prostate cancer	3.39e-05	0.000164	CcSEcCtD
Dolasetron—Diarrhoea—Epirubicin—prostate cancer	3.28e-05	0.000158	CcSEcCtD
Dolasetron—Hypersensitivity—Doxorubicin—prostate cancer	3.27e-05	0.000158	CcSEcCtD
Dolasetron—Asthenia—Doxorubicin—prostate cancer	3.18e-05	0.000154	CcSEcCtD
Dolasetron—Dizziness—Epirubicin—prostate cancer	3.17e-05	0.000153	CcSEcCtD
Dolasetron—Pruritus—Doxorubicin—prostate cancer	3.14e-05	0.000152	CcSEcCtD
Dolasetron—Diarrhoea—Doxorubicin—prostate cancer	3.04e-05	0.000147	CcSEcCtD
Dolasetron—Rash—Epirubicin—prostate cancer	3.02e-05	0.000146	CcSEcCtD
Dolasetron—Dermatitis—Epirubicin—prostate cancer	3.02e-05	0.000146	CcSEcCtD
Dolasetron—Headache—Epirubicin—prostate cancer	3e-05	0.000145	CcSEcCtD
Dolasetron—Dizziness—Doxorubicin—prostate cancer	2.93e-05	0.000142	CcSEcCtD
Dolasetron—Rash—Doxorubicin—prostate cancer	2.8e-05	0.000135	CcSEcCtD
Dolasetron—Dermatitis—Doxorubicin—prostate cancer	2.8e-05	0.000135	CcSEcCtD
Dolasetron—Headache—Doxorubicin—prostate cancer	2.78e-05	0.000134	CcSEcCtD
Dolasetron—CYP2D6—Metabolism—HSD17B3—prostate cancer	1.45e-05	0.000189	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ACSL4—prostate cancer	1.45e-05	0.000189	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	1.44e-05	0.000188	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ACSL4—prostate cancer	1.44e-05	0.000188	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—HSD17B3—prostate cancer	1.44e-05	0.000188	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	1.42e-05	0.000186	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ARG2—prostate cancer	1.39e-05	0.000182	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—UMPS—prostate cancer	1.39e-05	0.000182	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PHGDH—prostate cancer	1.39e-05	0.000182	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—RFK—prostate cancer	1.38e-05	0.000181	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—MBTPS1—prostate cancer	1.38e-05	0.000181	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PGAM2—prostate cancer	1.38e-05	0.000181	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NAGLU—prostate cancer	1.38e-05	0.000181	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—SULT2B1—prostate cancer	1.38e-05	0.000181	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—AOX1—prostate cancer	1.38e-05	0.000181	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTM3—prostate cancer	1.38e-05	0.000181	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ARG2—prostate cancer	1.38e-05	0.00018	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—UMPS—prostate cancer	1.38e-05	0.00018	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PHGDH—prostate cancer	1.38e-05	0.00018	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	1.37e-05	0.000179	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—LDHB—prostate cancer	1.36e-05	0.000178	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—LDHB—prostate cancer	1.35e-05	0.000177	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP3A5—prostate cancer	1.34e-05	0.000175	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP3A5—prostate cancer	1.33e-05	0.000173	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—AMACR—prostate cancer	1.31e-05	0.000171	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP3A43—prostate cancer	1.31e-05	0.000171	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—SRD5A2—prostate cancer	1.31e-05	0.000171	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—DEGS1—prostate cancer	1.31e-05	0.000171	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NAT1—prostate cancer	1.31e-05	0.000171	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—UCP3—prostate cancer	1.29e-05	0.000169	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTA3—prostate cancer	1.29e-05	0.000169	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PDHA1—prostate cancer	1.29e-05	0.000169	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—TCN2—prostate cancer	1.29e-05	0.000169	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PDHA1—prostate cancer	1.28e-05	0.000167	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTA3—prostate cancer	1.28e-05	0.000167	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—UCP3—prostate cancer	1.28e-05	0.000167	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—TCN2—prostate cancer	1.28e-05	0.000167	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.25e-05	0.000163	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—HSD3B1—prostate cancer	1.23e-05	0.000161	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—SLC22A3—prostate cancer	1.23e-05	0.000161	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—SLC22A3—prostate cancer	1.22e-05	0.00016	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—HSD3B1—prostate cancer	1.22e-05	0.00016	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—LPL—prostate cancer	1.18e-05	0.000155	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTA4—prostate cancer	1.18e-05	0.000154	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—TBXAS1—prostate cancer	1.18e-05	0.000154	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTA4—prostate cancer	1.17e-05	0.000153	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—TBXAS1—prostate cancer	1.17e-05	0.000153	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTA2—prostate cancer	1.15e-05	0.000151	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	1.14e-05	0.00015	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTA2—prostate cancer	1.14e-05	0.000149	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—SULT1A1—prostate cancer	1.14e-05	0.000149	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ABCG5—prostate cancer	1.14e-05	0.000149	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ABCG5—prostate cancer	1.13e-05	0.000147	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—SULT1A1—prostate cancer	1.13e-05	0.000147	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—B4GALT4—prostate cancer	1.11e-05	0.000146	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—HPGD—prostate cancer	1.11e-05	0.000146	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTA1—prostate cancer	1.11e-05	0.000145	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTA1—prostate cancer	1.1e-05	0.000144	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—HSD3B2—prostate cancer	1.1e-05	0.000144	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTO1—prostate cancer	1.1e-05	0.000144	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NAT2—prostate cancer	1.1e-05	0.000144	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTO1—prostate cancer	1.09e-05	0.000142	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NAT2—prostate cancer	1.09e-05	0.000142	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—HSD3B2—prostate cancer	1.09e-05	0.000142	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PLCB2—prostate cancer	1.05e-05	0.000138	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—LRP2—prostate cancer	1.05e-05	0.000138	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP2C18—prostate cancer	1.05e-05	0.000138	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—TNFRSF21—prostate cancer	1.05e-05	0.000137	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	1.05e-05	0.000137	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PLCB2—prostate cancer	1.04e-05	0.000136	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—LRP2—prostate cancer	1.04e-05	0.000136	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP2C18—prostate cancer	1.04e-05	0.000136	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—P4HB—prostate cancer	1.03e-05	0.000135	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—P4HB—prostate cancer	1.02e-05	0.000134	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—MTAP—prostate cancer	1.02e-05	0.000133	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP7B1—prostate cancer	1.02e-05	0.000133	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—SLC22A1—prostate cancer	1e-05	0.000131	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—SLC22A1—prostate cancer	9.96e-06	0.00013	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—SULT1E1—prostate cancer	9.93e-06	0.00013	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—SRD5A1—prostate cancer	9.93e-06	0.00013	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	9.84e-06	0.000129	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—SULT2A1—prostate cancer	9.79e-06	0.000128	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—SULT2A1—prostate cancer	9.7e-06	0.000127	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—MED12—prostate cancer	9.63e-06	0.000126	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GNG5—prostate cancer	9.55e-06	0.000125	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—MED12—prostate cancer	9.54e-06	0.000125	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ACSL4—prostate cancer	9.47e-06	0.000124	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—HSD17B3—prostate cancer	9.47e-06	0.000124	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GNG5—prostate cancer	9.47e-06	0.000124	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NCOA3—prostate cancer	9.2e-06	0.00012	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NCOA3—prostate cancer	9.12e-06	0.000119	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—UMPS—prostate cancer	9.08e-06	0.000119	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PHGDH—prostate cancer	9.08e-06	0.000119	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ARG2—prostate cancer	9.08e-06	0.000119	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	8.96e-06	0.000117	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—LDHB—prostate cancer	8.91e-06	0.000116	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—HPGDS—prostate cancer	8.78e-06	0.000115	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP3A5—prostate cancer	8.74e-06	0.000114	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP2C19—prostate cancer	8.72e-06	0.000114	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—HPGDS—prostate cancer	8.7e-06	0.000114	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP2C19—prostate cancer	8.65e-06	0.000113	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ACHE—prostate cancer	8.51e-06	0.000111	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTT1—prostate cancer	8.51e-06	0.000111	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—TCN2—prostate cancer	8.44e-06	0.00011	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PDHA1—prostate cancer	8.44e-06	0.00011	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTA3—prostate cancer	8.44e-06	0.00011	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—UCP3—prostate cancer	8.44e-06	0.00011	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTT1—prostate cancer	8.44e-06	0.00011	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ACHE—prostate cancer	8.44e-06	0.00011	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP2A6—prostate cancer	8.42e-06	0.00011	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP2A6—prostate cancer	8.34e-06	0.000109	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	8.31e-06	0.000109	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—AKR1C3—prostate cancer	8.19e-06	0.000107	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PRKACB—prostate cancer	8.14e-06	0.000107	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—AKR1C3—prostate cancer	8.12e-06	0.000106	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PRKACB—prostate cancer	8.07e-06	0.000106	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP17A1—prostate cancer	8.06e-06	0.000105	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—SLC22A3—prostate cancer	8.05e-06	0.000105	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—HSD3B1—prostate cancer	8.05e-06	0.000105	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP17A1—prostate cancer	7.99e-06	0.000104	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	7.88e-06	0.000103	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—TBXAS1—prostate cancer	7.72e-06	0.000101	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTA4—prostate cancer	7.72e-06	0.000101	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NCOA2—prostate cancer	7.68e-06	0.0001	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NCOA2—prostate cancer	7.61e-06	9.96e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTA2—prostate cancer	7.52e-06	9.84e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—SULT1A1—prostate cancer	7.43e-06	9.72e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ABCG5—prostate cancer	7.43e-06	9.72e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—SLC5A5—prostate cancer	7.33e-06	9.58e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—SLC5A5—prostate cancer	7.26e-06	9.5e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTA1—prostate cancer	7.26e-06	9.5e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NAT2—prostate cancer	7.18e-06	9.39e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTO1—prostate cancer	7.18e-06	9.39e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—HSD3B2—prostate cancer	7.18e-06	9.39e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP2E1—prostate cancer	7.16e-06	9.36e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP2E1—prostate cancer	7.09e-06	9.28e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NQO1—prostate cancer	7.08e-06	9.25e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NQO1—prostate cancer	7.01e-06	9.17e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—TH—prostate cancer	6.97e-06	9.12e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—TH—prostate cancer	6.91e-06	9.04e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP3A4—prostate cancer	6.9e-06	9.02e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PLCB2—prostate cancer	6.88e-06	9e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—LRP2—prostate cancer	6.88e-06	9e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP2C18—prostate cancer	6.88e-06	9e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	6.87e-06	8.98e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP3A4—prostate cancer	6.84e-06	8.95e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	6.81e-06	8.9e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP1B1—prostate cancer	6.78e-06	8.87e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—P4HB—prostate cancer	6.75e-06	8.83e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP1B1—prostate cancer	6.72e-06	8.8e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GGT1—prostate cancer	6.57e-06	8.59e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—SLC22A1—prostate cancer	6.57e-06	8.59e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GGT1—prostate cancer	6.51e-06	8.52e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NCOA1—prostate cancer	6.47e-06	8.46e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NCOA1—prostate cancer	6.42e-06	8.39e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—SULT2A1—prostate cancer	6.4e-06	8.37e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP19A1—prostate cancer	6.38e-06	8.34e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP19A1—prostate cancer	6.32e-06	8.27e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—MED12—prostate cancer	6.29e-06	8.23e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GNG5—prostate cancer	6.24e-06	8.17e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—RXRA—prostate cancer	6.15e-06	8.05e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—RXRA—prostate cancer	6.1e-06	7.98e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NCOA3—prostate cancer	6.02e-06	7.87e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	5.93e-06	7.76e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—COMT—prostate cancer	5.93e-06	7.75e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTP1—prostate cancer	5.9e-06	7.72e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—COMT—prostate cancer	5.88e-06	7.69e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTP1—prostate cancer	5.85e-06	7.65e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ITPR1—prostate cancer	5.81e-06	7.59e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ITPR1—prostate cancer	5.76e-06	7.53e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—HPGDS—prostate cancer	5.74e-06	7.51e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP2C19—prostate cancer	5.7e-06	7.46e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	5.66e-06	7.4e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTT1—prostate cancer	5.57e-06	7.28e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ACHE—prostate cancer	5.57e-06	7.28e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP2A6—prostate cancer	5.5e-06	7.2e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—TYMS—prostate cancer	5.49e-06	7.18e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—TYMS—prostate cancer	5.44e-06	7.11e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTM1—prostate cancer	5.42e-06	7.09e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTM1—prostate cancer	5.38e-06	7.03e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—AKR1C3—prostate cancer	5.35e-06	7e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PRKACB—prostate cancer	5.32e-06	6.96e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—LPL—prostate cancer	5.32e-06	6.96e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—LPL—prostate cancer	5.28e-06	6.9e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP17A1—prostate cancer	5.27e-06	6.89e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP1A1—prostate cancer	5.14e-06	6.72e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ERCC2—prostate cancer	5.1e-06	6.67e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP1A1—prostate cancer	5.1e-06	6.67e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ERCC2—prostate cancer	5.05e-06	6.61e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NCOA2—prostate cancer	5.02e-06	6.57e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—MTHFR—prostate cancer	4.79e-06	6.27e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—SLC5A5—prostate cancer	4.79e-06	6.26e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—MTHFR—prostate cancer	4.75e-06	6.21e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PPARA—prostate cancer	4.7e-06	6.15e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP2E1—prostate cancer	4.68e-06	6.12e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PPARA—prostate cancer	4.66e-06	6.1e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NQO1—prostate cancer	4.63e-06	6.05e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—TH—prostate cancer	4.56e-06	5.96e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP1B1—prostate cancer	4.43e-06	5.8e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CAV1—prostate cancer	4.42e-06	5.78e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CAV1—prostate cancer	4.38e-06	5.73e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GGT1—prostate cancer	4.3e-06	5.62e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NCOA1—prostate cancer	4.23e-06	5.53e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.19e-06	5.48e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP19A1—prostate cancer	4.17e-06	5.45e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PIK3CG—prostate cancer	4.03e-06	5.27e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—RXRA—prostate cancer	4.02e-06	5.26e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PIK3CG—prostate cancer	3.99e-06	5.22e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—COMT—prostate cancer	3.88e-06	5.07e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTP1—prostate cancer	3.86e-06	5.05e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—INS—prostate cancer	3.81e-06	4.99e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ITPR1—prostate cancer	3.8e-06	4.97e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—INS—prostate cancer	3.78e-06	4.94e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CREBBP—prostate cancer	3.73e-06	4.88e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CREBBP—prostate cancer	3.7e-06	4.84e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—TYMS—prostate cancer	3.59e-06	4.69e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTM1—prostate cancer	3.55e-06	4.64e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PIK3CD—prostate cancer	3.54e-06	4.63e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PIK3CD—prostate cancer	3.51e-06	4.59e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—LPL—prostate cancer	3.48e-06	4.55e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP1A1—prostate cancer	3.36e-06	4.4e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NOS3—prostate cancer	3.34e-06	4.37e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ERCC2—prostate cancer	3.33e-06	4.36e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NOS3—prostate cancer	3.31e-06	4.33e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—MTHFR—prostate cancer	3.13e-06	4.1e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PIK3CB—prostate cancer	3.09e-06	4.04e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PPARA—prostate cancer	3.07e-06	4.02e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PIK3CB—prostate cancer	3.06e-06	4e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PTGS2—prostate cancer	3.06e-06	4e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PTGS2—prostate cancer	3.03e-06	3.96e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CAV1—prostate cancer	2.89e-06	3.78e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PTEN—prostate cancer	2.67e-06	3.49e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PTEN—prostate cancer	2.64e-06	3.46e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.63e-06	3.44e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—EP300—prostate cancer	2.54e-06	3.33e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—EP300—prostate cancer	2.52e-06	3.3e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—INS—prostate cancer	2.49e-06	3.26e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CREBBP—prostate cancer	2.44e-06	3.19e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.31e-06	3.03e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NOS3—prostate cancer	2.19e-06	2.86e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.02e-06	2.64e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PTGS2—prostate cancer	2e-06	2.61e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.88e-06	2.46e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PIK3CA—prostate cancer	1.86e-06	2.44e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PTEN—prostate cancer	1.74e-06	2.28e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—EP300—prostate cancer	1.66e-06	2.17e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—AKT1—prostate cancer	1.54e-06	2.01e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—AKT1—prostate cancer	1.52e-06	1.99e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.23e-06	1.61e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—AKT1—prostate cancer	1e-06	1.31e-05	CbGpPWpGaD
